BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 33993188)

  • 1. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
    Hasib Sidiqi M; Gertz MA
    Blood Cancer J; 2021 May; 11(5):90. PubMed ID: 33993188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
    Gertz MA
    Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
    Gertz MA; Dispenzieri A
    JAMA; 2020 Jul; 324(1):79-89. PubMed ID: 32633805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2020 Jul; 95(7):848-860. PubMed ID: 32267020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG,kappa monoclonal gammopathy of unknown significance with AL amyloidosis simulating giant cell arteritis.
    Pompilian VM; Tănăseanu Ş; Badea C; Zurac S; Socoliuc C; Badelita S; Botez E; Antohe M
    Rom J Intern Med; 2017 Sep; 55(3):179-182. PubMed ID: 28467313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A systemic disease mimicking a rheumatoid arthritis].
    Legrand M; Nouvier M; Paulin L; Deschamps B; Pialat JB; Coury F
    Rev Med Interne; 2019 Dec; 40(12):831-836. PubMed ID: 31444022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AL amyloidosis: untangling new therapies.
    Bal S; Landau H
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):682-688. PubMed ID: 34889374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review.
    Latif A; Lateef N; Razzaq F; Kapoor V; Ahsan MJ; Ashfaq M; Iftikhar A; Anwer F; Holmberg M; William P
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(4):274-283. PubMed ID: 33256586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.
    Muchtar E; Dispenzieri A; Gertz MA; Kumar SK; Buadi FK; Leung N; Lacy MQ; Dingli D; Ailawadhi S; Bergsagel PL; Fonseca R; Hayman SR; Kapoor P; Grogan M; Abou Ezzeddine OF; Rosenthal JL; Mauermann M; Siddiqui M; Gonsalves WI; Kourelis TV; Larsen JT; Reeder CB; Warsame R; Go RS; Murray DL; McPhail ED; Dasari S; Jevremovic D; Kyle RA; Lin Y; Lust JA; Russell SJ; Hwa YL; Fonder AL; Hobbs MA; Rajkumar SV; Roy V; Sher T
    Mayo Clin Proc; 2021 Jun; 96(6):1546-1577. PubMed ID: 34088417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future Developments in Light Chain Amyloidosis Management.
    Rodriguez M; Lenihan D; Merlini G
    Am J Med; 2022 Apr; 135 Suppl 1():S53-S57. PubMed ID: 35081388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of renal function in a patient diagnosed with concurrent amyloid amyloidosis and immunoglobulin light chain amyloidosis.
    Watanabe R; Ito K; Yasuno T; Abe Y; Hamauchi A; Yasunaga T; Sasatomi Y; Hisano S; Saito T; Nakashima H
    Nihon Jinzo Gakkai Shi; 2016; 58(5):668-74. PubMed ID: 30375826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathy Associated with Systemic Amyloidosis.
    Kaku M; Berk JL
    Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.